CoChat
Sign Up
Cited by 636Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.

Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice

Open access
Lasagna-Reeves, Cristian A, Castillo-Carranza, Diana L, Sengupta, Urmi, Clos, Audra L, Jackson, George R, Kayed, Rakez·2011·Molecular Neurodegeneration
DOI 10.1186/1750-1326-6-39PMC PMC3224595
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: The correlation between neurofibrillary tangles of tau and disease progression in the brains of Alzheimer's disease (AD) patients remains an area of contention. Innovative data are emerging from biochemical, cell-based and transgenic mouse studies that suggest that tau oligomers, a pre-filament form of tau, may be the most toxic and pathologically significant tau aggregate. Results: Here we report that oligomers of recombinant full-length human tau protein are neurotoxic in vivo after subcortical stereotaxic injection into mice. Tau oligomers impaired memory consolidation, whereas tau fibrils and monomers did not. Additionally, tau oligomers induced synaptic dysfunction by reducing the levels of synaptic vesicle-associated proteins synaptophysin and septin-11. Tau oligomers produced mitochondrial dysfunction by decreasing the levels of NADH-ubiquinone oxidoreductase (electron transport chain complex I), and activated caspase-9, which is related to the apoptotic mitochondrial pathway. Conclusions: This study identifies tau oligomers as an acutely toxic tau species in vivo, and suggests that tau oligomers induce neurodegeneration by affecting mitochondrial and synaptic function, both of which are early hallmarks in AD and other tauopathies. These results open new avenues for neuroprotective intervention strategies of tauopathies by targeting tau oligomers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1750-1326-6-39

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Experimental design and characterization of tau samples. (A) Mice were divided into four groups, one injected with tau oligomers and PBS, a second group injected with tau fibrils and PBS a third group injected with tau monomers and PBS, and a fourth group injected with tau heparin fibrils and PBS used as a control (*). (B) Schematic representation of a coronal section of a mouse brain with * indicating the injection sites of the tau preparations in PBS. (C) FPLC profile of tau oligomers injected into mice brains. (D) AFM image showing homogeneous population of tau oligomers (scale bar = 140 nm). (E) AFM image of tau fibrils (scale bar = 70 nm). (F) AFM images of tau fibrils prepared with heparin (scale bar = 50 nm).
Figure 1 Experimental design and characterization of tau samples. (A) Mice were divided into four groups, one injected with tau oligomers and PBS, a second group injected with tau fibrils and PBS a third group injected with tau monomers and PBS, and a fourth group injected with tau heparin fibrils and PBS used as a control (*). (B) Schematic representation of a coronal section of a mouse brain with * indicating the injection sites of the tau preparations in PBS. (C) FPLC profile of tau oligomers injected into mice brains. (D) AFM image showing homogeneous population of tau oligomers (scale bar = 140 nm). (E) AFM image of tau fibrils (scale bar = 70 nm). (F) AFM images of tau fibrils prepared with heparin (scale bar = 50 nm).CC BY · PubMed Central
Figure 2 Tau oligomers impaired the recognition memory in mice. (A) Effects of tau oligomers, fibrils, and monomers on memory were investigated in C57BL/6 mice by using the object recognition task. Histograms indicate the percentage of exploration of the familiar and novel objects. Mice injected with monomers or fibrils spent significantly more time investigating the novel object versus mice injected with tau oligomers, indicating impaired memory, as shown by their inability to recognize the familiar object. #p < 0.01 vs. novel object. (B) Histograms show the corresponding discrimination index (mean ± SD) for the data shown in A. *p < 0.01. As a control, behavioral analyses were performed on mice without injection.
Figure 2 Tau oligomers impaired the recognition memory in mice. (A) Effects of tau oligomers, fibrils, and monomers on memory were investigated in C57BL/6 mice by using the object recognition task. Histograms indicate the percentage of exploration of the familiar and novel objects. Mice injected with monomers or fibrils spent significantly more time investigating the novel object versus mice injected with tau oligomers, indicating impaired memory, as shown by their inability to recognize the familiar object. #p < 0.01 vs. novel object. (B) Histograms show the corresponding discrimination index (mean ± SD) for the data shown in A. *p < 0.01. As a control, behavioral analyses were performed on mice without injection.CC BY · PubMed Central
Figure 3 In vivo neurotoxicity of tau oligomers. A-D) Nuclear staining (Hematoxylin) of the hippocampal region CA1 from the hemispheres of mice injected with tau preparations or PBS (Scale bar = 20 μm). E-H) Neuronal staining using the antibody NeuN show neuronal damage in the area injected with tau oligomers (E) in comparison with the other hemispheres injected with fibrils (F) monomers (G) and PBS (H) (scale bar = 10 μm). (I-L) Higher toxicity of tau oligomers versus fibrils, monomers and PBS. Neurodegenerative pyramidal cells in the CA1 hippocampal region were stained with Fluoro-Jade B, emitting green fluorescence (scale bar = 10 μm). M) Number of Fluoro-Jade B positive cells/Total number of cells in the CA1 region, 63% of cells showed signs of damage in the group injected with tau oligomers, compared to less than 6.5% in the group injected with tau fibrils. Data are represented as the mean ± SE. *p < 0.01.
Figure 3 In vivo neurotoxicity of tau oligomers. A-D) Nuclear staining (Hematoxylin) of the hippocampal region CA1 from the hemispheres of mice injected with tau preparations or PBS (Scale bar = 20 μm). E-H) Neuronal staining using the antibody NeuN show neuronal damage in the area injected with tau oligomers (E) in comparison with the other hemispheres injected with fibrils (F) monomers (G) and PBS (H) (scale bar = 10 μm). (I-L) Higher toxicity of tau oligomers versus fibrils, monomers and PBS. Neurodegenerative pyramidal cells in the CA1 hippocampal region were stained with Fluoro-Jade B, emitting green fluorescence (scale bar = 10 μm). M) Number of Fluoro-Jade B positive cells/Total number of cells in the CA1 region, 63% of cells showed signs of damage in the group injected with tau oligomers, compared to less than 6.5% in the group injected with tau fibrils. Data are represented as the mean ± SE. *p < 0.01.CC BY · PubMed Central
Figure 4 Tau oligomers induce synaptic dysfunction. (A) Representative Western blot of mouse hippocampus homogenate. The levels of synaptophysin, synapsin-1, and septin-11 were measured by band quantification and normalized with the levels of tubulin. PBSo indicates representative bands of hippocampal area injected with PBS in mice also injected with tau oligomers, PBSf indicates PBS injection in mice also injected with tau fibrils, and PBSm indicates PBS injection in mice also injected with tau monomers. (B) Synaptophysin levels were significantly lower in the hemispheres injected with tau oligomers in comparison with the ones injected with fibrils, monomers, or PBS. (C) No significant differences in the levels of synapsin-1 were observed. (D) Only the hemisphere injected with tau oligomers presents a decrease in the level of septin-11. Data are represented as the mean ± SE. *p < 0.01, n = 6
Figure 4 Tau oligomers induce synaptic dysfunction. (A) Representative Western blot of mouse hippocampus homogenate. The levels of synaptophysin, synapsin-1, and septin-11 were measured by band quantification and normalized with the levels of tubulin. PBSo indicates representative bands of hippocampal area injected with PBS in mice also injected with tau oligomers, PBSf indicates PBS injection in mice also injected with tau fibrils, and PBSm indicates PBS injection in mice also injected with tau monomers. (B) Synaptophysin levels were significantly lower in the hemispheres injected with tau oligomers in comparison with the ones injected with fibrils, monomers, or PBS. (C) No significant differences in the levels of synapsin-1 were observed. (D) Only the hemisphere injected with tau oligomers presents a decrease in the level of septin-11. Data are represented as the mean ± SE. *p < 0.01, n = 6CC BY · PubMed Central
Figure 5 Decrease in synaptophysin in mice injected with tau oligomers. Brain sections were stained with antibody to the presynaptic marker synaptophysin (green) nuclear staining with DAPI (blue). All images were taken from the CA1 region. Hemispheres injected with tau oligomers exhibited a decreased in synaptophysin (A). No decrease in the signal was observed in the hemispheres injected with fibrils (B), monomers (C), and PBS (D). (Scale bars = 10 μm.)
Figure 5 Decrease in synaptophysin in mice injected with tau oligomers. Brain sections were stained with antibody to the presynaptic marker synaptophysin (green) nuclear staining with DAPI (blue). All images were taken from the CA1 region. Hemispheres injected with tau oligomers exhibited a decreased in synaptophysin (A). No decrease in the signal was observed in the hemispheres injected with fibrils (B), monomers (C), and PBS (D). (Scale bars = 10 μm.)CC BY · PubMed Central
Figure 6 Tau oligomers induce mitochondrial alterations. (A) Representative western blot of mouse brain homogenate. The levels of complex I, complex V, and caspase-9 were measured by band quantification and normalized with the levels of tubulin. Abbreviations are as in Fig. 4. (B) Complex I levels were significantly lower in the hemisphere injected with tau oligomers in comparison with the ones injected with fibrils or monomers. (C) No differences in the levels of complex V were observed in any of the groups. (D) Caspase-9 activation was significantly higher in tau oligomer groups over both tau fibril- and monomer-injected groups. (E-G) Double staining between human tau-specific antibody HT7 (green fluorescence) and mitochondrial porin antibody (red fluorescence) demonstrates the internalization of tau oligomers in CA1 cells and their interaction with the mitochondria. (H) The co-localization of tau oligomers with mitochondria was confirmed by ICA of the signal. Data are represented as mean ± SE. *p < 0.01, n = 6.
Figure 6 Tau oligomers induce mitochondrial alterations. (A) Representative western blot of mouse brain homogenate. The levels of complex I, complex V, and caspase-9 were measured by band quantification and normalized with the levels of tubulin. Abbreviations are as in Fig. 4. (B) Complex I levels were significantly lower in the hemisphere injected with tau oligomers in comparison with the ones injected with fibrils or monomers. (C) No differences in the levels of complex V were observed in any of the groups. (D) Caspase-9 activation was significantly higher in tau oligomer groups over both tau fibril- and monomer-injected groups. (E-G) Double staining between human tau-specific antibody HT7 (green fluorescence) and mitochondrial porin antibody (red fluorescence) demonstrates the internalization of tau oligomers in CA1 cells and their interaction with the mitochondria. (H) The co-localization of tau oligomers with mitochondria was confirmed by ICA of the signal. Data are represented as mean ± SE. *p < 0.01, n = 6.CC BY · PubMed Central
Figure 7 Caspase-9 activation in hemisphere injected with tau oligomers. Immunofluorescence using an antibody for pro-caspase-9 was performed. (A and B) Caspase-9 activation (green fluorescence) was observed in hemispheres injected with tau oligomers (A) or fibrils (B). However, the levels of activation were significantly higher in the hemispheres injected with oligomers compared with fibrils, which is not significant. (C and D). No activation of caspase-9 was observed in the hemispheres injected with tau monomers (C) or PBS (D). Nucleus was stained with DAPI (blue). (Scale bars = 10 μm.).
Figure 7 Caspase-9 activation in hemisphere injected with tau oligomers. Immunofluorescence using an antibody for pro-caspase-9 was performed. (A and B) Caspase-9 activation (green fluorescence) was observed in hemispheres injected with tau oligomers (A) or fibrils (B). However, the levels of activation were significantly higher in the hemispheres injected with oligomers compared with fibrils, which is not significant. (C and D). No activation of caspase-9 was observed in the hemispheres injected with tau monomers (C) or PBS (D). Nucleus was stained with DAPI (blue). (Scale bars = 10 μm.).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 84 references

Cited by

Sorted by citations

Items 101–200 of 636

Related

See all

Metadata

Authors
Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Sengupta, U., Clos, A. L., Jackson, G. R., & Kayed, R.
Affiliations
The University of Texas Medical Branch at Galveston (US)
Corresponding author
Kayed, Rakez
ORCID
Venue
Molecular Neurodegeneration
Publisher
Springer Science and Business Media LLC
Published
2011-06-06
Volume
6
Issue
1
Pages
39-39
ISSN
1750-1326 (ISSN-L)
DOI
10.1186/1750-1326-6-39
PMC
PMC3224595
OpenAlex
W1968276382
Cited by
633
References
84
Citations by year
2026: 52 · 2025: 67 · 2024: 46 · 2023: 53 · 2022: 52 · 2021: 51 · 2020: 57 · 2019: 43 · 2018: 44 · 2017: 35 · 2016: 27 · 2015: 33 · 2014: 27 · 2013: 28 · 2012: 12
FWCI
15.93
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Molecular Neurodegeneration (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Alzheimer's Drug Discovery Foundation
  • Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
tau oligomers, tauopathy, Alzheimer's disease, neurotoxicity, memory consolidation, synaptic dysfunction, synaptophysin, mitochondrial dysfunction, complex I, caspase-9, apoptosis, neurofibrillary tangles, stereotactic injection, neurodegeneration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review